CN106167517B - 抗胶质瘤活性物质链霉缩酚肽p11b及制备和应用 - Google Patents
抗胶质瘤活性物质链霉缩酚肽p11b及制备和应用 Download PDFInfo
- Publication number
- CN106167517B CN106167517B CN201610225504.2A CN201610225504A CN106167517B CN 106167517 B CN106167517 B CN 106167517B CN 201610225504 A CN201610225504 A CN 201610225504A CN 106167517 B CN106167517 B CN 106167517B
- Authority
- CN
- China
- Prior art keywords
- depsipeptides
- strepto
- liquid
- drug
- streptomyces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010002156 Depsipeptides Proteins 0.000 title claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title claims abstract description 14
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000126 substance Substances 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 241001312734 Streptomyces parvulus Species 0.000 claims abstract description 18
- 206010018338 Glioma Diseases 0.000 claims abstract description 16
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 15
- 241000933218 Streptomyces parvus Species 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 239000000470 constituent Substances 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 6
- 238000001819 mass spectrum Methods 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 claims 1
- 150000001343 alkyl silanes Chemical group 0.000 claims 1
- 238000011068 loading method Methods 0.000 claims 1
- 238000005191 phase separation Methods 0.000 claims 1
- 238000010898 silica gel chromatography Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000001348 anti-glioma Effects 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 241001446247 uncultured actinomycete Species 0.000 abstract 1
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 238000007865 diluting Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- -1 Azoles amine Chemical class 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一种具有抗胶质瘤活性的化合物链霉缩酚肽P11B(streptodepsipeptide P11B,),是海洋天然活性物质,从海洋放线菌小链霉菌(Streptomyces parvulus P11‑23B)中分离培养纯化获得。经试验证实链霉缩酚肽P11B可显著抑制多种胶质瘤细胞的增殖,可在制备治疗脑胶质瘤药物中的应用。所述药物为链霉缩酚肽P11B活性成分单独,或与其它药物或有效成分一起,与药学上可接受的载体组成的药物。本发明首次发现了该化合物的抗胶质瘤活性,为制备抗脑胶质瘤药物提供新的途径。所述的链霉缩酚肽P11B的化学结构式为:
Description
技术领域
本发明属医药领域,涉及一种抗肿瘤活性化合物链霉缩酚肽P11B(streptodepsipeptide P11B)及该化合物在制备治疗脑胶质瘤药物方面的应用。
背景技术
脑胶质瘤是脑颅内最常见和最恶性的脑肿瘤,占所有恶性脑肿瘤的70%。胶质瘤由于所处的位置特殊,累及许多重要的脑功能区,使得临床上手术难度大而且不容易将肿瘤全部切除,所以药物对胶质瘤的治疗尤为重要。但是,全球抗胶质瘤药物严重缺乏,替莫唑胺是目前临床上唯一可单独用于胶质瘤治疗的一线药物,而且,包括替莫唑胺在内的现有治疗胶质瘤药物的疗效有限,多有严重不足,突出表现为:(1)多为化学品,毒副作用大;(2)肿瘤细胞对药物的严重耐药性;(3)血脑屏障阻碍了药物到达脑内发挥其疗效。因此,需要研究发现新的抗胶质瘤药物。
链霉缩酚肽P11B(streptodepsipeptide P11B)是从海洋细菌小链霉菌P11-23B(Streptomyces parvulus P11-23B)中分离得到的新化合物,该化合物对多种不同胶质瘤细胞的增殖具有显著的抑制作用,因此,链霉缩酚肽P11B在制备抗胶质瘤药物方面具有应用前景。
发明内容
本发明的第一个目的是提供一种具有抗胶质瘤活性的化合物链霉缩酚肽P11B(streptodepsipeptide P11B,1),所述的链霉缩酚肽P11B为一新化合物,其化学结构式为:
链霉缩酚肽P11B(streptodepsipeptide P11B)是通过以下步骤而获得的:
(1)小链霉菌(Streptomyces parvulus P11-23B)的分离培养
取空气干燥的海泥用海水稀释成一定的浓度,取一定量的样品稀释液均匀分散到含有固体培养基的培养皿中,在室温条件下培养一定时间后,将不同的菌落分别转移到另一含有固 体培养基的培养皿中,在室温条件下继续培养一定时间。最后将生长良好的单一菌落(P11-23B)接种到斜面培养基培养后置4℃冰箱保存备用。
所述的海泥和海水是从浙江舟山东海海域中获得;所述样品稀释液的浓度为1×10-6~1×10-4g/mL;所述的样品稀释液的取样量为100~300μL;所述培养皿所含的固体培养基为高氏琼脂(Gause′s agar)培养基或其它固体培养基;所述的斜面培养基为高氏琼脂培养基或其它固体斜面培养基;所述的室温培养温度为20~30℃;所述的培养时间为7~15天。
(2)小链霉菌(Streptomyces parvulus P11-23B)的菌种鉴定
上述步骤(1)分离培养所获得的菌株用目前实验室普遍使用的16S rDNA序列分析方法鉴定菌株P11-23B的种类,确定为小链霉菌,分类命名为Streptomyces parvulus P11-23B,已被中国典型培养物保藏中心-武汉中心保藏,保藏编号CCTCC NO:M 2015675,保藏日:2015.11.12; 保藏地址:中国,武汉,武汉大学。
(3)小链霉菌Streptomyces parvulus P11-23B发酵菌液的制备
取链霉菌Streptomyces parvulus P11-23B的菌落接种到含有一定量的液体高氏培养基的三角烧瓶中,将含有P11-23B菌种的培养液在室温条件下振荡培养一定时间后以制备菌种液。最后将菌种液转入含有一定量的液体高氏培养基的三角烧瓶,在室温条件下振荡发酵培养一定时间后,得到具有抗肿瘤活性的P11-23B的发酵菌液。
所述的液体高氏培养基用量为100-200mL;所述的三角培养瓶为250或500mL;所述的室温培养温度为20~30℃;所述振荡的转速为160-180rpm;所述的培养时间为5~15天。
(4)链霉缩酚肽P11B的提取分离纯化
菌株P11-23B的发酵菌液用乙酸乙酯萃取得到乙酸乙酯萃取物,乙酸乙酯萃取物用十八烷基硅烷键合硅胶(ODS)柱层析分离,分别用70%和100%的甲醇洗脱,100%的甲醇洗脱液合并后经减压浓缩得到的残留物用HPLC分离,得到纯化合物链霉缩酚肽P11B。
所述柱层析的ODS用量与上量的样品量比例是40~60g:1.0g;所述的高效液相分离条件是:Agilent 1260高效液相色谱仪,Agilent 1260DAD检测器,Agilent Zorbax SB-C18色谱柱(250×9.4mm,5μm),100%甲醇为流动相,柱温26℃,检测波长210nm,流速为1.0mL/min。
(5)链霉缩酚肽P11B的结构鉴定
链霉缩酚肽P11B(streptodepsipeptide P11B)的结构是根据它们的一维和二维的NMR光谱分析、高分辨质谱数据、以及化学降解等方法来鉴定的。
本发明的第二个目的是提供链霉缩酚肽P11B在制备治疗脑胶质瘤药物中的应用。所述的链霉缩酚肽P11B可显著抑制多种胶质瘤细胞的增殖。所述药物为链霉缩酚肽P11B活性成分单独,或与其它药物或有效成分一起,与药学上可接受的载体组成的药物。
本发明发现了一个新的海洋天然活性物质链霉缩酚肽P11B,并首次发现了该化合物的抗胶质瘤活性,链霉缩酚肽P11B在制备抗脑胶质瘤药物方面具有应用前景。
附图说明
图1是小链霉菌Streptomyces parvulus P11-23B的菌落图。
图2-6是链霉缩酚肽P11B(streptodepsipeptide P11B)的氢谱。
图7-13是链霉缩酚肽P11B(streptodepsipeptide P11B)的碳谱。
图14-16是链霉缩酚肽P11B(streptodepsipeptide P11B)的HSQC谱。
图17-22是链霉缩酚肽P11B(streptodepsipeptide P11B)的HMBC谱。
图23是链霉缩酚肽P11B(streptodepsipeptide P11B)的高分辨质谱。
图24是链霉缩酚肽P11B(streptodepsipeptide P11B)对胶质瘤细胞增殖的抑制作用。
具体实施例
以下结合附图和实施例对本发明作进一步详细描述。但是,本发明不限于这些实施例。
1.小链霉菌(Streptomyces parvulus P11-23B)的分离培养
取空气干燥的海泥1克用海水稀释成浓度为1×10-6g/mL的样品稀释液,取200μL的样品稀释液均匀分散到含有高氏琼脂(Gause′s agar)固体培养基的培养皿中,在28℃条件下培养7天后,将不同的菌落分别转移到另一含有高氏琼脂固体培养基的培养皿中,在28℃条件下继续培养7天。最后将生长良好的单一菌落(P11-23B)接种到高氏琼脂斜面培养基培养后置4℃冰箱保存备用。
2.小链霉菌(Streptomyces parvulus P11-23B)的菌种鉴定
使用16S rDNA序列分析方法鉴定所获得菌株P11-23B的种类。
2.1实验试剂及仪器
PCR试剂:EX Taq酶(TaKaRa),dNTP(TaKaRa),引物(Invitrogen合成),引物序列是:TACGGYTACCTTGTTACGACTT和AGAGTTTGATCMTGGCTCAG
Marker:DL5000
实验仪器:离心机,电泳仪,PCR仪,ABI 3730XL测序仪。
2.2实验步骤
细菌基因组DNA抽提
电泳检测
PCR扩增
a.PCR反应体系
b.PCR反应条件
c.电泳检测
d.测序:切胶纯化测序
e.分析结果:拼接序列。
2.3实验结果
拼接后的序列为:
AACCACTTCGGTGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATACTGACCTTCACGGGCATCTGTGAAGGTCGAAAGCTCCGGCGGTGCAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGCACTAGGTGTGGGCAACATTCCACGTTGTCCGTGCCGCAGCTAACGCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAACGTCCAGAGATGGGCGCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCCCGTGTTGCCAGCAGG CCCTTGTGGTGCTGGGGACTCACGGGAGACCGCCGGGGTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGGTACAATGAGCTGCGATACCGCAAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCTCAACCC。
以上获得的16S rDNA序列与美国NCBI GenBank数据库比较,其结果表明:菌株P11-23B的16S rDNA序列与GenBank库中的Streptomyces parvulus strain PFS10的16SrDNA序列有99%的相似性(登录号:KJ789323.1)。因此,本发明所获得的海洋菌株P11-23B确定为小链霉菌(Streptomyces parvulus P11-23B)(附图1)。小链霉菌(Streptomycesparvulus P11-23B)菌株已被中国典型培养物保藏中心-武汉中心保藏,保藏编号CCTCCNO:M 2015675。
3.小链霉菌(Streptomyces parvulus P11-23B)发酵菌液的制备
取链霉菌Streptomyces parvulus P11-23B的菌落接种到含有200mL液体高氏培养基的500mL三角烧瓶中,将含有P11-23B菌种的培养液在28℃条件下旋转(180rpm)振摇培养7天后得到菌种液。将5mL菌种液转入含有200mL液体高氏培养基的500mL三角烧瓶中,在28℃条件下旋转(180rpm)振摇培养7天,得到具有抗肿瘤活性的P11-23B的发酵菌液(50.0升)。
4.链霉缩酚肽P11B(streptodepsipeptide P11B)的提取分离纯化
实验3获得的发酵菌液(50.0升)用乙酸乙酯萃取得到乙酸乙酯萃取物(7.56克),乙酸乙酯萃取物用十八烷基硅烷键合硅胶(ODS,500克)柱层析分离,分别用2000mL的70%和100%甲醇洗脱,100%的甲醇洗脱液合并后减压浓缩的残留物(1.38克)用HPLC分离(仪器:Agilent 1260;层析柱:Agilent Zorbax SB-C18,250×9.4mm,5μm;流动相:100%甲醇;柱温:26℃;检测波长:210nm;流速:1.0mL/min),得到链霉缩酚肽P11B(1,127mg,tR17.1min)。
链霉缩酚肽P11B为无色粉末;分子式C52H86N6O18;[α]D 25+26.7(c 0.50,MeOH);IR(KBr)vmax 2963,2871,2360,1743,1655,1536,1463,1193,1094m-1;高分辨质谱(HRESIMS)为m/z[M-H]-1081.5899(计算值C52H85N6O18 1081.5920)。经手性氨基酸柱和气相色谱分析并与标准品对照,链霉缩酚肽P11B的酸水解产物鉴定为D-缬氨酸(D-Val)、L-缬氨酸(L-Val)、L-乳酸(L-Lac)、D-α-羟基异戊酸(D-Hiv)。
根据链霉缩酚肽P11B的1H谱(附图2-6)、13C谱(附图7-13)、HSQC谱(附图14-16)、HMBC谱(附图17-22)、高分辨质谱(附图23)和化学降解,链霉缩酚肽P11B的结构鉴定为一个新化合物,其13C和1H NMR信号归属见表一。
表一、链霉缩酚肽P11B的碳和氢信号归属
5.链霉缩酚肽P11B(streptodepsipeptide P11B)抑制胶质瘤细胞增殖的作用
大鼠脑胶质瘤C6细胞和人脑胶质瘤U251细胞用DMEM和10%FBS培养基在37℃和5%二氧化碳的孵化箱中培养,而人脑胶质瘤U87-MG和SHG-44细胞分别用MEM培养基和RPMI-1640培养基在37℃和5%二氧化碳的孵化箱中培养,经过三代培养的细胞用于本发明的实验研究。
用磺酰罗丹明B(SRB)法测定肿瘤细胞存活率,阿霉素(Doxorubicin)用于阳性药对照。细胞接种于96孔板中,贴壁24h后加入不同浓度的链霉缩酚肽P11B。药物处理72h后用SRB染色,用酶标仪测定515nm处的吸收光度值,检测肿瘤细胞的存活率,计算链霉缩酚肽P11B抑制胶质瘤细胞增殖的IC50值。实验结果表明:链霉缩酚肽P11B显著抑制胶质瘤细胞的增殖,其IC50值分别为0.1-1.4μM(表二,附图24)。
表二、链霉缩酚肽P11B抑制胶质瘤细胞增殖的作用(IC50:μM)
Claims (4)
1.一种具有抗胶质瘤活性的化合物链霉缩酚肽P11B,其特征在于,其化学结构式为:
。
2.根据权利要求1所述的一种具有抗胶质瘤活性的化合物链霉缩酚肽P11B的制备方法,其特征在于,通过以下步骤获得:
(1) 小链霉菌(Streptomyces parvulus )P11-23B发酵菌液的制备
取小链霉菌(Streptomyces parvulus) P11-23B的菌落接种到含有液体高氏培养基的三角烧瓶中,将含有P11-23B菌种的培养液在室温条件下振荡培养后以制备菌种液,最后将菌种液转入含有液体高氏培养基的三角烧瓶,在室温条件下振荡发酵培养,得到具有抗肿瘤活性的P11-23B的发酵菌液;小链霉菌P11-23B,分类命名为Streptomyces parvulus,已被中国典型培养物保藏中心-武汉中心保藏,保藏编号CCTCC NO:M 2015675,保藏日:2015.11.12;
(2) 链霉缩酚肽P11B的提取分离纯化
菌株P11-23B的发酵菌液用乙酸乙酯萃取得到乙酸乙酯萃取物,乙酸乙酯萃取物用十八烷基硅烷键合硅胶柱层析分离,分别用70%和100%的甲醇洗脱,100%的甲醇洗脱液合并后经减压浓缩得到的残留物用高效液相色谱分离,得到纯化合物链霉缩酚肽P11B;
所述柱层析的十八烷基硅烷键合硅胶用量与上样的样品量比例是40-60 g∶1.0 g;所述的高效液相分离条件是:Agilent 1260高效液相色谱仪,Agilent 1260 DAD 检测器,Agilent Zorbax SB-C18 色谱柱 250ⅹ9.4 mm,5μm,100%甲醇为流动相,柱温 26℃,检测波长210 nm,流速为1.0 mL/min;
(3) 链霉缩酚肽P11B的结构鉴定
根据一维和二维的NMR光谱分析、高分辨质谱数据、以及化学降解方法鉴定链霉缩酚肽P11B的结构,具体结构式同权利要求1所示。
3.根据权利要求2所述的制备方法,其特征在于,步骤(1)所述的液体高氏培养基用量为100-200 mL;所述的三角烧瓶为250 或500 mL;所述的室温培养温度为20-30℃;所述振荡的转速为160-180 rpm;所述的培养时间为5-15天。
4.根据权利要求1所述的一种链霉缩酚肽P11B在制备治疗脑胶质瘤药物中的应用,其特征在于,所述药物为链霉缩酚肽P11B活性成分单独,或与其它药物或有效成分一起,与药学上可接受的载体组成的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610225504.2A CN106167517B (zh) | 2016-04-12 | 2016-04-12 | 抗胶质瘤活性物质链霉缩酚肽p11b及制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610225504.2A CN106167517B (zh) | 2016-04-12 | 2016-04-12 | 抗胶质瘤活性物质链霉缩酚肽p11b及制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106167517A CN106167517A (zh) | 2016-11-30 |
CN106167517B true CN106167517B (zh) | 2019-08-09 |
Family
ID=57358935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610225504.2A Active CN106167517B (zh) | 2016-04-12 | 2016-04-12 | 抗胶质瘤活性物质链霉缩酚肽p11b及制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106167517B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110172485B (zh) * | 2019-05-13 | 2021-02-12 | 浙江大学 | 抗胶质瘤活性物质吡咯螺酮碱g的制备和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102757908A (zh) * | 2012-05-11 | 2012-10-31 | 中国科学院南海海洋研究所 | 链霉菌和吲哚倍半萜类化合物及其制备方法和在制备抗菌抗肿瘤药物中的应用 |
CN102993188A (zh) * | 2012-11-03 | 2013-03-27 | 浙江大学 | 弗霉素b及其制备方法和用途 |
CN103421706A (zh) * | 2013-05-15 | 2013-12-04 | 中国科学院南海海洋研究所 | 链霉菌、新化合物及其制备方法和在制备抗菌抗肿瘤药物中的应用 |
CN105112322A (zh) * | 2015-08-07 | 2015-12-02 | 浙江大学 | 灰霉醌a和b及其制备方法和医药用途 |
-
2016
- 2016-04-12 CN CN201610225504.2A patent/CN106167517B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102757908A (zh) * | 2012-05-11 | 2012-10-31 | 中国科学院南海海洋研究所 | 链霉菌和吲哚倍半萜类化合物及其制备方法和在制备抗菌抗肿瘤药物中的应用 |
CN102993188A (zh) * | 2012-11-03 | 2013-03-27 | 浙江大学 | 弗霉素b及其制备方法和用途 |
CN103421706A (zh) * | 2013-05-15 | 2013-12-04 | 中国科学院南海海洋研究所 | 链霉菌、新化合物及其制备方法和在制备抗菌抗肿瘤药物中的应用 |
CN105112322A (zh) * | 2015-08-07 | 2015-12-02 | 浙江大学 | 灰霉醌a和b及其制备方法和医药用途 |
Non-Patent Citations (2)
Title |
---|
Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis;Ye X 等;《Phytochemistry》;20161231;第135卷;第151-159页 * |
基于肿瘤代谢靶标的抗脑胶质瘤海洋天然活性物质的发现和研究;梁英 等;《中国药学会会议论文集》;20151026;第267-272页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106167517A (zh) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101599982B1 (ko) | 노노무라에아 종으로부터의 고리형 펩티드, 그에 대한 생산 프로세스 및 이를 포함하는 마이코박테리아 관련 질병의 치료 혹은 예방을 위한 약학적 조성물 | |
CN105670968B (zh) | 一种海洋天然抗胶质瘤活性物质及制备和用途 | |
CN106167517B (zh) | 抗胶质瘤活性物质链霉缩酚肽p11b及制备和应用 | |
CN111646993B (zh) | 海洋抗胶质瘤活性物质异壁咔啉碱c及制备和用途 | |
CN109106702A (zh) | 源于草酸青霉的4-4’异构化黑麦酮酸d在结肠癌方面的应用 | |
CN105112322B (zh) | 灰霉醌a和b及其制备方法和医药用途 | |
Singh et al. | Purification and chemical characterization of antimicrobial compounds from a new soil isolate Streptomyces rimosus MTCC 10792 | |
CN111747955B (zh) | 海洋抗胶质瘤活性物质异壁咔啉碱a及制备和用途 | |
CN106047751B (zh) | 一株拟诺卡氏放线菌及其活性代谢产物的分离方法与应用 | |
CN109762046B (zh) | 环肽类抗生素及其制备方法和在制备抗结核分枝杆菌药物中的应用 | |
CN105968067B (zh) | 缬氨霉素b及制备和医药用途 | |
CN108949610B (zh) | 一种链霉菌和以链霉菌产生的angucycline类化合物及其制备与应用 | |
CN102070507B (zh) | 一种三吲哚化合物及其制备方法和用途 | |
CN109384828A (zh) | 抗耐药菌活性物质青霉碱醚a及制备和用途 | |
Li et al. | Purification and identification of an actinomycin D analogue from actinomycetes associated with Ganoderma applanatum via magnetic molecularly imprinted polymers and tandem mass spectrometry | |
CN105886421B (zh) | 一株拟无枝菌酸菌及利用该菌制备特戊依罗霉素的方法 | |
CN108660169A (zh) | 一种发酵制备棘孢菌素类抗生素的方法 | |
CN104211780A (zh) | 一种环缩肽类化合物及其制备方法和用途 | |
EP0359062A2 (en) | Antibiotic GE 2270 | |
CN109824746B (zh) | 一种友霉素类化合物及其制备方法和应用 | |
CN106434406B (zh) | 一种产生疏螺旋体素的放线菌及其应用 | |
CN105061445B (zh) | 源于桔青霉的penicitrinine A及其制备抗人胃癌药物的应用 | |
CN105017272B (zh) | 源于桔青霉的penicitrinine A及其制备抗人乳腺癌药物的应用 | |
CN110218759A (zh) | 抗胶质瘤活性物质青霉碱醚a的制备和用途 | |
CN109106707A (zh) | 源于草酸青霉的4-4’异构化黑麦酮酸d在宫颈癌方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |